LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Drug Company Buyout to Boost Development of Liver Disease Drugs

By LabMedica International staff writers
Posted on 20 Apr 2016
Print article
A strategic buyout will broaden the role of an American pharmaceutical research and manufacturing company in the area of liver diseases.
 
 
 
The biopharmaceutical company Gilead Sciences (Foster City, CA, USA) has announced the purchase of Nimbus Apollo Inc., a subsidiary of Nimbus Therapeutics LLC (Cambridge, MA, USA). Gilead is set to pay 400 million USD for Nimbus Apollo, and the parent company could receive up to another 800 million USD, if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.
 
 
 
Implementation of the agreement will give Gilead access to the experimental drug NDI-010976, which is being tested for the treatment of non-alcoholic steatohepatitis, known by the acronym NASH. This disorder causes inflammation, cell damage, progressive scarring, and cirrhosis of the liver. An estimated 15 million Americans suffer from NASH.
 
 
 
In February 2016, the drug NDI-010976 was awarded [US] Food and Drug Administration "fast-track" designation, which speeds up regulatory review and approval. The drug blocks two forms of the enzyme acetyl CoA carboxylase (ACC), which is involved in cellular fatty acid metabolism.
 
 
 
Dr. Norbert Bischofberger, CSO at Gilead, said, "The acquisition will complement and further strengthen Gilead's ongoing efforts to address unmet needs in NASH."
 
 
 
In addition to the acquisition of NDI-010976, the purchase brings to Gilead Nimbus' breakthrough computational chemistry platform that was designed to enable rapid discovery, design, and tweaking of potential medicinal compounds.
 
 
Related Links: 
 
Gilead Sciences
 
Nimbus Therapeutics LLC


 
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more